% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sun:163304,
      author       = {Sun, Qiang and Melino, Gerry and Amelio, Ivano and Jiang,
                      Jingting and Wang, Ying and Shi, Yufang},
      title        = {{R}ecent advances in cancer immunotherapy.},
      journal      = {Discover oncology},
      volume       = {12},
      number       = {1},
      issn         = {1868-8497},
      address      = {[New York]},
      publisher    = {Springer},
      reportid     = {DZNE-2022-00084},
      pages        = {27},
      year         = {2021},
      note         = {Journal: Discover Oncology, ISSN: 2730-6011},
      abstract     = {Cancer immunotherapy represents a major advance in the cure
                      of cancer following the dramatic advancements in the
                      development and refinement of chemotherapies and
                      radiotherapies. In the recent decades, together with the
                      development of early diagnostic techniques, immunotherapy
                      has significantly contributed to improving the survival of
                      cancer patients. The immune-checkpoint blockade agents have
                      been proven effective in a significant fraction of standard
                      therapy refractory patients. Importantly, recent advances
                      are providing alternative immunotherapeutic tools that could
                      help overcome their limitations. In this mini review, we
                      provide an overview on the main steps of the discovery of
                      classic immune-checkpoint blockade agents and summarise the
                      most recent development of novel immunotherapeutic
                      strategies, such as tumour antigens, bispecific antibodies
                      and TCR-engineered T cells.},
      subtyp        = {Review Article},
      keywords     = {Cancer immunotherapy (Other) / Cancer survival (Other) /
                      Immune check point blockade (Other) / KRas (Other) / T cell
                      receptor (Other) / p53 (Other)},
      cin          = {AG Nicotera},
      ddc          = {610},
      cid          = {I:(DE-2719)5000018},
      pnm          = {351 - Brain Function (POF4-351)},
      pid          = {G:(DE-HGF)POF4-351},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35201440},
      pmc          = {pmc:PMC8777500},
      doi          = {10.1007/s12672-021-00422-9},
      url          = {https://pub.dzne.de/record/163304},
}